Organicell Regenerative Medicine, Inc. reported the results of its Phase 1/2A research program for its biologic therapeutic, ZofinTM, which contains high concentrations of nanoparticles, including exosomes, growth factors, and bio-active proteins. These results focus on the safety outcomes across three separate studies. Organicell has completed a Phase 1 study in knee osteoarthritis and a second study in patients with moderate-to-severe COVID-19.

In addition, a trial involving patients with "long-haul" COVID-19 acquired sufficient data to end additional patient enrollment earlier this year and is expected to be completed in October 2023. Notably, across all three studies, with over 20 patients treated with ZofinTM (not including a similar number of patients treated with placebo), there have been no reported therapy-related safety events or significant adverse events.